Please assess the completion status of the following clinical trial:

Trial Title: Effects of REnal Denervation for Resistant Hypertension on Exercise Diastolic Function and Regression of Atherosclerosis and the Evaluation of NEW Methods Predicting A successfuL Renal Sympathetic Denervation (RENEWAL-EXERCISE, -REGRESS, and -PREDICT Trial From RENEWAL RDN Registry)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20-85 years with resistant hypertension defined as systolic BP\>140 mmHg (\>130 mmHg for diabetes) or diastolic BP\>90mmHg (\>80 mmHg for diabetes) despite adequate administration of 3 or more different classes of anti-hypertensive medications including diuretics with good adherence and adequate treatment regimen.~* All agents should be prescribed at optimal dose amounts. BP was based on an average of 3 office BP readings measured according to the general guidelines. Patients are adhering to a stable drug regimen including 3 or more antihypertensive medications (with no changes for a minimum of 2 weeks prior to enrollment).~* Patients provided with the written, informed consent to participate in this study~Exclusion Criteria:~* Hemodynamically or anatomically significant renal artery abnormalities, main renal arteries \< 4 mm in diameter or \< 20 mm in length, or.prior renal artery intervention~* Estimated glomerular filtration rate (eGFR) of \< 30mL/min/1.73m2, using the MDRD calculation~* Hemodynamically significant valvular heart disease~* History of congestive heart failure with reduce LV ejection fraction of less than 35%~* CVA in the prior 3 months~* ST-segment elevation MI within 48 hours~* Scheduled or planned surgery or cardiovascular intervention in the next 6 months.~* Patients with chronic debilitating disease with life expectancy of less than 1 year~* Patients taking hormone replace treatment and/or oral contraceptives; pregnant, nursing or planning to be pregnant~* Chronic liver cirrhosis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- RD group (Type: EXPERIMENTAL): Renal denervation group
- Control group (Type: ACTIVE_COMPARATOR): Control group

Based on this trial design, predict the completion outcome and termination type (if applicable).